Brief: Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity
06/08/2025 13:51
Aug 6 (Reuters) - MetaVia Inc MTVA.O: METAVIA EXTENDS 48 MG MAD PORTION OF ITS PHASE 1 CLINICAL TRIAL OF DA-1726 FOR THE TREATMENT OF OBESITY TO 8 WEEKS AND ANNOUNCES FIFTH WEEKLY DOSE IN FIRST PATIENT METAVIA INC - TOP-LINE DATA EXPECTED IN Q4 2025 Source text: ID:nPn3PNjRva Further company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise